Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 2/20 | 0.52 |
| ▸ | SYK | P43405 | 2/20 | 0.52 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | TP53 | P04637 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | AURKA | O14965 | 4/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | KCNN3 | Q9UGI6 | 1/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19690922 | 1.00 | ADORA2A (0.52) | ADORA2ASYKPOLBTP53MAPT | |
| SCHEMBL19690920 | 1.00 | ADORA2A (0.52) | ADORA2ASYKPOLBTP53MAPT | |
| SCHEMBL19700514 | 0.93 | ADORA2A (0.54) | ADORA2ASYKPOLBTP53MAPT | |
| SCHEMBL4219122 | 0.80 | POLB (0.72) | ADORA2APOLBTP53MAPTLMNA | |
| SCHEMBL19700443 | 0.80 | POLB (0.54) | ADORA2APOLBTP53MAPTLMNA | |
| SCHEMBL19690865 | 0.78 | POLB (0.58) | ADORA2APOLBTP53MAPTLMNA | |
| SCHEMBL19690850 | 0.77 | POLB (0.46) | ADORA2APOLBTP53MAPTAURKA | |
| SCHEMBL19690833 | 0.75 | ADORA2A (0.52) | ADORA2APOLBTP53MAPTLMNA | |
| SCHEMBL4219790 | 0.74 | AURKA (0.59) | ADORA2APOLBTP53MAPTAURKA | |
| SCHEMBL19690878 | 0.74 | KCNN3 (0.54) | ADORA2APOLBTP53MAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170355708-A1 | POTASSIUM CHANNEL MODULATORS | CADENT THERAPEUTICS, INC. | 2017-12-14 | — | — | US | disclosed |
| US-20170355708-A1 | POTASSIUM CHANNEL MODULATORS | CADENT THERAPEUTICS, INC. | 2017-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355708-A1 | POTASSIUM CHANNEL MODULATORS | KCNJ11, KCNJ2, KCNJ1 | ADORA2A 1792/4885SYK 3744/4885POLB 4779/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.